clinical trial · NCT04788043
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
Hodgkin LymphomaClassic Hodgkin LymphomaRelapsed Classical Hodgkin LymphomaRefractory Classic Hodgkin LymphomaMagrolimabPembrolizumabPET/CT
brief summary
The purpose of this study is to test the safety and efficacy of magrolimab in combination with pembrolizumab in patients with Hodgkin lymphoma.
started
Jun 21, 2022
primary completion
Oct 11, 2024
completion
Aug 29, 2025
last updated
Jun 30, 2026
detailed description
Primary Objectives:
\- To assess the complete remission (CR) rate of magrolimab in combination with pembrolizumab in adult subjects with relapsed or refractory cHL
Secondary Objectives:
* To assess the safety and tolerability of magrolimab in combination with pembrolizumab in adult subjects with relapsed or refractory cHL * To assess the overall response rate (ORR)
official title
A Phase 2 Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol